The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology

Journal of Ophthalmology

Volumn 2015, Issue , 2015, Pages

  Rusnak, Stepan ^a   Vrzalova, Jindra ^a,b   Sobotova, Marketa ^a   Hecova, Lenka ^a   Ricarova, Renata ^a   Topolcan, Ondrej ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944234886     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2015/424783     Document Type: Article

References (19)

1. E. Adeghate, P. Schattner, and E. Dunn, "An update on the etiology and epidemiology of diabetes mellitus," Annals of the New York Academy of Sciences, vol. 1084, pp. 1-29, 2006.
2. R. Klein and B. Klein, The Beaver Dam Eye Study, 1987-2010, http: //www. bdeyestudy. org/.
3. B. E. K. Klein, "Overview of epidemiologic studies of diabetic retinopathy," Ophthalmic Epidemiology, vol. 14, no. 4, pp. 179-183, 2007.
4. R. Simó, E. Carrasco, M. Garca-Ramrez, and C. Hernández, "Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy," Current Diabetes Reviews, vol. 2, no. 1, pp. 71-98, 2006.
5. R. F. Gariano and T. W. Gardner, "Retinal angiogenesis in development and disease," Nature, vol. 438, no. 7070, pp. 960-966, 2005.
6. R. F. Spaide, "Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography," Retina, vol. 31, no. 5, pp. 829-837, 2011.
7. K. L. Kellar and M. A. Iannone, "Multiplexed microspherebased flow cytometric assays," Experimental Hematology, vol. 30, no. 11, pp. 1227-1237, 2002.
8. R. Maier,M. Weger, E.-M. Haller-Schober et al. , "Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients," Molecular Vision, vol. 14, pp. 637-643, 2008.
9. P. Murugeswari, D. Shukla, A. Rajendran, R. Kim, P. Namperumalsamy, and V. Muthukkaruppan, "Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease," Retina, vol. 28, no. 6, pp. 817-824, 2008.
10. T. Yoshimura, K.-H. Sonoda, M. Sugahara et al. , "Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases," PLoS ONE, vol. 4, no. 12, Article IDe8158, 2009.
11. H. Freyberger, M. Bröcker, H. Yakut et al. , "Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy," Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 2, pp. 106-109, 2000.
12. H. Funatsu, H. Yamashita, T. Mimura, H. Noma, S. Nakamura, and S. Hori, "Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines," Eye, vol. 21,no. 3, pp. 377-382, 2007.
13. S. J. Curnow, F. Falciani, O. M. Durrani et al. , "Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis," Investigative Ophthalmology and Visual Science, vol. 46, no. 11, pp. 4251-4259, 2005.
14. M. Funding, T. K. Hansen, J. Gjedsted, and N. Ehlers, "Simultaneous quantification of 17 immune mediators in aqueous humour frompatients with corneal rejection," Acta Ophthalmologica Scandinavica, vol. 84, no. 6, pp. 759-765, 2006.
15. S. Rusnak, J. Vrzalova, L. Hecová, M. Kozova, O. Topolcan, and R. Ricarova, "Defining the seriousness of proliferative vitreoretinopathy by aspiration of cytokines from the anterior chamber," Biomarkers in Medicine, vol. 7, no. 5, pp. 759-767, 2013.
16. H. J. Sohn, D. H. Han, I. T. Kimet al. , "Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema," American Journal of Ophthalmology, vol. 152, no. 4, pp. 686-694, 2011.
17. M. Saint-Geniez, A. S. R. Maharaj, T. E. Walshe et al. , "Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors," PLoS ONE, vol. 3, no. 11, Article ID e3554, 2008.
18. P. A. Campochiaro, D. F. Choy, D. V. Do et al. , "Monitoring ocular drug therapy by analysis of aqueous samples," Ophthalmology, vol. 116, no. 11, pp. 2158-2164, 2009.
19. T. U. Krohne, N. Eter, F. G. Holz, andC. H. Meyer, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans," The American Journal of Ophthalmology, vol. 146, no. 4, pp. 508-512, 2008.